SciELO - Scientific Electronic Library Online

 
vol.24 número2Hospitalizaciones por reacciones adversas a medicamentos y abandono del tratamiento farmacológico en el hospital universitarioFactores de riesgo para aterosclerosis en enfermedades autoinmunitarias índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Links relacionados

Compartir


Revista Médica del Uruguay

versión On-line ISSN 1688-0390

Resumen

DANZA, Álvaro; CRISTIANI, Federico  y  TAMOSIUNAS, Gustavo. Trimetazidina en el tratamiento del angor estable. Rev. Méd. Urug. [online]. 2008, vol.24, n.2, pp.109-117. ISSN 1688-0390.

Summary Introduction: ischaemic cardipathy is a highly prevalent disease in our country. It is caused by an imbalance between the oxygen requirement of the myocardium and the oxygen supplied to it. Conventional therapeutics focuses on modification of hemodynamics variables . However, a significant number of patients still evidenced symptoms after applying these therapeutics. Thus, new ways of drug (non-hemodynamic) interventions are being sought, such as metabolic kinds of intervention, by increasing myocardial energy substrates yield. Trimetazidine is a drug that acts by modulating myocardial metabolism, proving to be a new and promising action mechanism. Objective: to update and perform a critical analysis of the information on the efficacy and safety of trimetazidine in treating stable angina pectoris that is currently available, thus learning about its usefulness in clinical practice and encouraging its rational use. Method: Medline, Lilacs and Cochrane Databases were searched, looking for information. To learn about its efficacy, controlled clinical trials, systematic reviews and meta-analysis were included. To learn about safety, notifications, series of cases and drug surveillance bulletins were also integrated. Results: studies conducted showed symptomatic improvement with trimetazidine, with no notifications of serious adverse effects, although elderly patients evidenced extrapyramidal symptoms. Conclusions: trimetazidine has been shown to improve symptoms in patients with stable angina pectoris. There is no information about its effects on "hard" variables such as mortality or myocardial infarction. As with all new drugs, active safety surveillance is advised.

Palabras clave : ANGINA PECTORIS [ terapia]; TRIMETAZIDINA [uso terapéutico]; EVALUACION DE MEDICAMENTOS; ANGINA PECTORIS [ therapy]; TRIMETAZIDINE [ therapeutic use]; DRUG EVALUATION.

        · resumen en Español | Francés | Portugués     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons